WEST PHARMACEUTICAL SERVICES INC: management transactions · United States · SEC (Form 4)

About WEST PHARMACEUTICAL SERVICES INC

West Pharmaceutical Services, Inc. (NYSE: WST) is a leading U.S.-listed healthcare and pharma infrastructure company headquartered in Exton, Pennsylvania, United States. West specializes in integrated containment and delivery solutions for injectable medicines, supplying critical components and systems to pharmaceutical, biotechnology, generic-drug and medical-device customers. Its franchise is built around highly engineered products where sterility, material science, regulatory compliance and supply reliability are essential. Founded in 1923, West has spent more than a century building expertise in materials science, product design and manufacturing. Over time, the company has evolved from a packaging-focused supplier into a strategic partner for the world’s major drug developers. That long operating history matters: in injectable medicines, customers value proven quality systems, validated manufacturing and deep technical support. West’s global headquarters is in Exton, Pennsylvania, and the company operates an international manufacturing, R&D and analytical-lab footprint. West’s business is organized mainly into two segments. Proprietary Products includes higher-value components and delivery platforms for injectable drugs, such as stoppers, seals, containment components, drug-delivery systems and specialized closure technologies marketed under names including Westar®, Envision®, NovaPure® and SmartDose®. Contract-Manufactured Products covers products made for third parties, including self-injection devices and other medical-device assemblies. This mix gives West both recurring consumables exposure and selected device-manufacturing opportunities. From a competitive standpoint, West is well positioned as a mission-critical supplier to pharmaceutical supply chains. The company’s advantages lie in its reputation for quality, its regulatory and formulation know-how, and its ability to manufacture at scale across multiple geographies. Those capabilities create meaningful barriers to entry, especially in biologics, high-volume injectable therapies, generics and advanced therapies. Recent company commentary has highlighted demand tied to GLP-1 therapies, obesity, diabetes and cell-and-gene therapy applications. Recent operating updates have been constructive. In first-quarter 2026, West reported strong revenue and adjusted EPS growth and raised full-year guidance. Management also announced an expansion of its Dublin facility to support high-volume injectable therapies, and the company continued to repurchase shares. These developments reinforce the view that West is combining organic growth, capacity investment and capital returns. For investors in France, Belgium and Switzerland, West Pharmaceutical Services is best viewed as a high-quality healthcare infrastructure business on the U.S. NYSE market, with a defensive profile, strong customer stickiness and exposure to durable long-term trends in injectable drug delivery.